DE69533873D1 - Krebstherapie mit lymphotoxin - Google Patents

Krebstherapie mit lymphotoxin

Info

Publication number
DE69533873D1
DE69533873D1 DE69533873T DE69533873T DE69533873D1 DE 69533873 D1 DE69533873 D1 DE 69533873D1 DE 69533873 T DE69533873 T DE 69533873T DE 69533873 T DE69533873 T DE 69533873T DE 69533873 D1 DE69533873 D1 DE 69533873D1
Authority
DE
Germany
Prior art keywords
lymphotoxin
cancer therapy
cancer
vivo
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533873T
Other languages
English (en)
Other versions
DE69533873T2 (de
Inventor
David V Goeddel
Grace H W Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69533873D1 publication Critical patent/DE69533873D1/de
Application granted granted Critical
Publication of DE69533873T2 publication Critical patent/DE69533873T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69533873T 1994-07-01 1995-06-26 Krebstherapie mit lymphotoxin Expired - Lifetime DE69533873T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US418314 1982-09-15
US26970494A 1994-07-01 1994-07-01
US269704 1994-07-01
US08/418,314 US5747023A (en) 1994-07-01 1995-04-07 Cancer therapy using lymphotoxin
PCT/US1995/008085 WO1996001121A1 (en) 1994-07-01 1995-06-26 Cancer therapy using lymphotoxin

Publications (2)

Publication Number Publication Date
DE69533873D1 true DE69533873D1 (de) 2005-01-27
DE69533873T2 DE69533873T2 (de) 2005-12-29

Family

ID=26953844

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533873T Expired - Lifetime DE69533873T2 (de) 1994-07-01 1995-06-26 Krebstherapie mit lymphotoxin

Country Status (10)

Country Link
US (1) US5747023A (de)
EP (1) EP0768889B1 (de)
JP (1) JPH10502371A (de)
AT (1) ATE285247T1 (de)
AU (1) AU712197B2 (de)
CA (1) CA2191696A1 (de)
DE (1) DE69533873T2 (de)
IL (1) IL114382A (de)
MX (1) MX9606559A (de)
WO (1) WO1996001121A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
ZA964382B (en) * 1995-06-06 1997-12-01 Genentech Inc Lymphotoxin and thrombopoietin for use in the treatment of cancer.
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP0832653A1 (de) 1996-09-20 1998-04-01 Max-Delbrück-Centrum Für Molekulare Medizin Verwenddung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200002203T2 (tr) * 1998-01-30 2000-12-21 Biogen, Inc Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
GB9808796D0 (en) * 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
CL2007002926A1 (es) * 2006-10-12 2008-05-16 Genentech Inc Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
US8067375B2 (en) 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2009062344A1 (fr) * 2007-11-16 2009-05-22 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Utilisation de lymphotoxine pour sensibiliser des cellules tumorales à des médicaments chimiothérapeutiques
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405601A (en) * 1981-05-21 1983-09-20 Cancer Research Center Extraction and purification of biologically active lymphokines
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
DE3613167A1 (de) * 1986-04-18 1987-10-29 Basf Ag Verwendung von tnf zur herstellung von arzneimitteln
JPS63245692A (ja) * 1987-04-01 1988-10-12 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシンまたはその組成物
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
AU3578189A (en) * 1988-04-27 1989-11-24 Immunomedics Inc. Improved radiotherapy

Also Published As

Publication number Publication date
AU712197B2 (en) 1999-10-28
IL114382A0 (en) 1995-10-31
US5747023A (en) 1998-05-05
AU2911595A (en) 1996-01-25
EP0768889A1 (de) 1997-04-23
MX9606559A (es) 1997-03-29
EP0768889B1 (de) 2004-12-22
ATE285247T1 (de) 2005-01-15
CA2191696A1 (en) 1996-01-18
JPH10502371A (ja) 1998-03-03
DE69533873T2 (de) 2005-12-29
WO1996001121A1 (en) 1996-01-18
IL114382A (en) 2005-12-18

Similar Documents

Publication Publication Date Title
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
NZ337493A (en) Use of a reovirus for treating Ras-mediated neoplasms
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
DE69533873D1 (de) Krebstherapie mit lymphotoxin
PL343462A1 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
MX9708401A (es) Genes reguladores de la cromatina.
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
IS5570A (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
TR199903074T2 (xx) Kanser tedavisinde HMG CoA ve farnesil transfer �nleyicileri.
PT980205E (pt) Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
MD798G2 (ro) Metoda de tratament a cancerului mamar
DK0938900T3 (da) Midler til forebyggelse/behandling af stomatitis
EP1234585A3 (de) Zusammensetzungen zur Vorbeugung oder Behandlung von Krebs
ES2012547A6 (es) Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas.
NZ506005A (en) Recombinant proteins derived from hgf and msp
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
UA43728A (uk) Спосіб лікування раку передміхурової залози

Legal Events

Date Code Title Description
8364 No opposition during term of opposition